CONRAY 43 DIN 00477095
Status: Cancelled Post Market
Holder: LIEBEL-FLARSHEIM CANADA INC
Health Canada record
| Active ingredient(s) | IOTHALAMATE MEGLUMINE 430 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravascular |
|---|
| Schedule | ETHICAL |
|---|
| Class | Human |
|---|
| ATC | V08AA04 IOTALAMIC ACID |
|---|
| Original market date | 31-Dec-1980 |
|---|
| Current status date | 07-May-2018 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Liebel-Flarsheim Canada Inc. — licence 102249, not currently licensed, last inspection rating C (2023-11-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IOTHALAMATE MEGLUMINE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 00223107 | CONRAY 30 | LIEBEL-FLARSHEIM CANADA INC | Solution | IOTHALAMATE MEGLUMINE 300 MG | Cancelled Post Market |
| 00131237 | CONRAY 60 | LIEBEL-FLARSHEIM COMPANY LLC | Solution | IOTHALAMATE MEGLUMINE 600 MG | Cancelled Post Market |
| 00274194 | CYSTO CONRAY INJ 43% | MALLINCKRODT CANADA INC. | Liquid | IOTHALAMATE MEGLUMINE 430 MG | Cancelled Post Market |
| 00397466 | CYSTO-CONRAY II | LIEBEL-FLARSHEIM COMPANY LLC | Solution | IOTHALAMATE MEGLUMINE 172 MG | Cancelled Post Market |
| 00131628 | VASCORAY | TYCO HEALTHCARE | Solution | IOTHALAMATE MEGLUMINE 520 MG; IOTHALAMATE SODIUM 260 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 16521 | 2015-01-13 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 13918 | 2012-11-30 | New Drug Submission (NDS) | Manufacturer name change |
| 676 | 2002-07-02 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
Request a quote for CONRAY 43
How to read a Canadian DIN record